Geron Corp.

FOSTER CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to participate in a fireside chat at the Goldman Sachs 47 th Annual Global Healthcare Conference on Monday, June 8, 2026 at 8:40 a.m. ET in Miami, FL. A live and archived audio webcast of the fireside chat will be available through the Investors & Media section of Geron’s website at . About Geron Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO ® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit or follow us on LinkedIn . Investors and Media Dawn Schottlandt Senior Vice President, Investor Relations and Corporate Affairs dschottlandt@geron.com

Cell therapies and precision biologics are driving new opportunities across longevity, cognitive health, and neurological disease sectors NEW YORK, May 20, 2026 /PRNewswire/ -- Market News Updates News Commentary - Cell-based therapies are quickly becoming one of the most talked-about areas in healthcare as researchers move beyond traditional drugs and focus on repairing and regenerating the body at the cellular level. Instead of only treating symptoms, scientists are now exploring ways to potentially reverse damage tied to aging and chronic disease. In the anti-aging space, stem cells, regenerative biologics, and senolytic therapies are being studied for their potential to restore tissue function, reduce inflammation, and support healthier aging overall. That shift in focus has sparked major interest from biotech companies and institutional investors alike. The global cell therapy market was valued at around $4.7 billion in 2023 and is expected to climb past $20 billion by 2030 as more therapies move closer to commercialization. Healthcare companies active in the markets this week include: Avaí Bio, Inc. (OTCQB: AVAI), Geron Corporation (NASDAQ: GERN), BioAge Labs, Inc. (NASDAQ: BIOA), Lineage Cell Therapeutics, Inc. (NYSE American: LCTX), Fate Therapeutics, Inc. (NASDAQ: FATE). At the same time, the broader longevity and anti-aging market continues gaining momentum as aging populations grow worldwide. Researchers are developing next-generation treatments aimed at removing senescent, or "zombie," cells that contribute to aging and disease while also working to regenerate damaged tissue and improve cognitive and physical function later in life. Many of these cell-based approaches are now being combined with gene therapies, immune-focused treatments, and personalized medicine strategies to create more targeted solutions. Industry forecasts suggest the global senolytics and anti-aging pharmaceuticals market could reach approximately $6.39 billion by 2030, driven by rising demand for longevity-focused therapies and growing research into age-related conditions like Alzheimer's and Parkinson's disease. Neurodegenerative disorders are also becoming a major area of focus for regenerative medicine as diseases such as Alzheimer's, Parkinson's, ALS, and multiple sclerosis continue to affect millions of people globally. Researchers are studying stem cell and regenerative neural therapies designed to repair damaged neurons, reduce inflammation in the brain, and potentially slow disease progression instead of simply managing symptoms. That push toward disease-modifying treatments is attracting substantial investment across both the biotech and pharmaceutical industries. Analysts estimate the broader neurodegenerative disease treatment market could grow from roughly $58.4 billion in 2025 to nearly $85 billion by 2032, while smaller niche markets tied to rare neurological disorders are also expected to expand as regenerative medicine technologies continue advancing through clinical development. Avaí Bio and Austrianova Complete GMP Master Cell Bank, Begin Viral Testing for Cell-Based Klotho Anti-Aging Therapy - Avaí Bio, Inc. (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced—together with its joint venture partner and global biotechnology firm, Austrianova— a major milestone in the Company's path to clinical trials, the completion of a Master Cell Bank (MCB) of genetically modified cells that overexpress the α-Klotho protein. Now, the MCB will undergo comprehensive testing to confirm the absence of pathogenic viruses, as well as standard assays to verify the MCB is free from adventitious agents such as bacteria, mycoplasma, fungi, and yeast to meet regulatory expectations, including those set by the FDA. This testing will be conducted independently by a top-tier, accredited third-party provider, separate from Austrianova, Avaí Bio, and their combined joint venture, Klothonova. Following successful completion, the next step will be the generation of a "Working Cell Bank" (WCB) using α-Klotho protein–overexpressing cells derived from the MCB. These cells will be used to manufacture the final Cell-in-a-Box® encapsulated clinical product. A Master Cell Bank is a GMP-compliant, fully characterized, and homogeneous collection of vials derived from a single clone. It serves as the critical starting material for the scale-up and production of cell therapies, ensuring product consistency while reducing risk by protecting against contamination, degradation, extraneous agents, and genetic instability. By establishing and maintaining a high-quality MCB as the primary source for all Working Cell Banks under Good Manufacturing Practice (GMP) standards, Avaí Bio and Austrianova strengthen the foundation for a reliable, scalable, and sustainable supply chain. This milestone marks a significant step forward in Klothonova's mission to develop a sustainable, cell-based approach to restoring declining levels of the α-Klotho "longevity protein" associated with aging. The approach is intended to address both general aging and age-related conditions, including kidney disease, neurodegenerative disorders, and vascular diseases. "We are pleased that this first step in the production phase of α-Klotho producing cells has been successfully completed. We look forward to the completion of the subsequent steps needed to fulfill our commitment to deliver safe, effective treatments for the ever-burgeoning array of aging associated diseases," said Chris Winter, Chief Executive Officer of Avaí Bio. Dr Brian Salmons, Chief Executive Officer of Austrianova, added, "The Austrianova team is pleased to have completed the production of the α-Klotho protein expressing cells on behalf of Klothonova, our Joint Venture with Avaí Bio. We look forward to completing the next steps that will culminate with the production of Cell-in-a-Box® encapsulated clinical product for application to patients." This milestone represents the most recent progress under the joint venture agreement signed in September 2025, which established Klothonova as a Nevada-based company equally owned by Avaí Bio and Austrianova's affiliate, SG Austria Pte. Ltd. The joint venture is dedicated to the sustainable production of α-Klotho—often referred to as the "longevity protein"—a key regulatory protein widely recognized for its anti-aging properties and protective effects on multiple organs, delivered through encapsulated cell-based therapies for patients. CONTINUED… Read this and more news for Avaí Bio at: In other recent developments and happenings in the biotech market include: Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, recently announced that the first real-world evidence study of RYTELO® (imetelstat) in patients with lower-risk myelodysplastic syndromes (LR-MDS) will be presented at the European Hematology Association (EHA) 2026 Congress. The retrospective and prospective investigator-sponsored study, conducted at the Moffitt Cancer Center, reported safety and clinical efficacy of imetelstat in advanced, heavily transfusion dependent patients with LR-MDS, including patients with extensive prior therapies and after luspatercept failure. Data from the retrospective portion of the study will be presented at the EHA 2026 Congress. "Imetelstat has become an important treatment option for patients with lower-risk myelodysplastic syndromes experiencing anemia and red blood cell transfusion burden, particularly in patients previously treated with ESAs or other therapies," said David A. Sallman, M.D., Associate Member, Malignant Hematology Department, Moffitt Cancer Center. "As treatment sequencing has emerged as an increasing area of focus in LR-MDS, real-world analyses such as this study can help provide additional context on how therapies are being used in routine clinical practice and across more diverse patient populations. We look forward to presenting these data at EHA 2026." BioAge Labs, Inc. (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, recently reported results from the Phase 1 clinical trial of BGE-102, a potent, structurally novel, orally available, brain-penetrant small molecule NLRP3 inhibitor. The full dataset, which includes a newly announced 60 mg once-daily cohort dosed for 21 days in participants with obesity and elevated inflammation, demonstrates that BGE-102 achieved potential best-in-class reductions in high-sensitivity C-reactive protein (hsCRP) and consistent reductions across multiple inflammatory biomarkers, with a favorable tolerability profile. Notably, the 60 mg dose achieved hsCRP and other biomarker reductions comparable to the previously reported 120 mg dose. Based on the full Phase 1 dataset, BioAge intends to initiate a dose-ranging Phase 2 cardiovascular risk proof-of-concept trial in the first half of 2026, with data anticipated in the second half of 2026. Lineage Cell Therapeutics, Inc. (NYSE American: LCTX), a clinical-stage biotechnology company developing "off the shelf" allogeneic cell therapies for serious medical conditions, recently announced that 36-month results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089) of RG6501 (OpRegen) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), were presented at the Foundation Fighting Blindness' Retinal Therapeutics Innovation Summit 2026. The presentation, "Retinal Pigment Epithelium (RPE) Cell Therapy in Geographic Atrophy Secondary to Age-related Macular Degeneration: 3 Year Results from the Phase 1/2a Study," was presented by Eyal Banin, M.D., Ph.D., Center for Retinal and Macular Degenerations, Department of Ophthalmology Hadassah-Hebrew University Medical Center and Faculty of Medicine, on behalf of Roche and Genentech, a member of the Roche Group. "We are excited that our partners continue to collect data and highlight positive clinical results from the OpRegen RPE cell therapy phase 1/2a program," stated Brian M. Culley, Lineage CEO. "We remain confident in the potential of OpRegen to address a significant medical need from a single administration, especially because long term clinical outcomes from RPE cell therapy are challenging the long-held view that GA is an irreversible condition, and currently available therapies have not demonstrated a visual benefit. The results presented by Dr. Banin include OCT images which indicate partial restoration of outer retinal structure, including the re-appearance of a retinal pigment epithelial layer as well as features associated with recovery of photoreceptors. It remains notable that among patients who received extensive coverage of OpRegen RPE cells across the area of atrophy (n=5), anatomical and functional benefits have lasted for at least three years, outcomes consistent with meaningful disease stabilization and even improvement. We are excited to see any additional insights which our partners, Roche and Genentech, may uncover from the ongoing GAlette study, which is a surgical optimization study intended to assess the best way to deliver OpRegen cell therapy to patients with GA secondary to age related macular degeneration." Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients for broad accessibility, recently reported financial results for the first quarter ended March 31, 2026, and provided a business update. "We are incredibly excited and focused on initiating RECLAIM-LN, our Phase 2 potentially registrational clinical trial of FT819 for the treatment of lupus nephritis to provide eligible trial patients a truly accessible CAR T-cell treatment option," said Bob Valamehr, Ph.D., MBA, President and Chief Executive Officer of Fate Therapeutics. "Our acceptance into the FDA's highly competitive CDRP Program, combined with our RMAT designation, reflects a recognition of the strength of our initial Phase 1 clinical data and provides a powerful regulatory foundation as we advance FT819 along an accelerated clinical pathway. With planned clinical advancement of FT819 on multiple fronts, next generation CAR T-cell programs entering clinical trials, a strong cash balance supporting our runway into 2028 and a team that continues to execute at the highest level, we believe 2026 will be a defining year for Fate Therapeutics." DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU'S market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU expects to be compensated forty nine hundred dollars for news coverage of the current press releases issued by Avaí Bio, Inc. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements. Contact Information: Media Contact email: [email protected] - +1(561)325-8757 Logo - SOURCE Market News Updates 21% more press release views with Request a Demo

Cell therapies and precision biologics are driving new opportunities across longevity, cognitive health, and neurological disease sectors 细胞疗法和精准生物制品正在推动长寿、认知健康和神经疾病领域的新机遇。NEW YORK 纽约, ，May 20, 2026 2026年5月20日/PRNewswire/ -- Market News Updates News Commentary - Cell-based therapies are quickly becoming one of the most talked-about areas in healthcare as researchers move beyond traditional drugs and focus on repairing and regenerating the body at the cellular level. Instead of only treating symptoms, scientists are now exploring ways to potentially reverse damage tied to aging and chronic disease. /PRNewswire/ -- 市场新闻更新 新闻评论 —— 基于细胞的疗法正迅速成为医疗保健领域最热门的话题之一，研究人员正在超越传统药物，专注于在细胞层面修复和再生身体。科学家们现在不仅致力于治疗症状，还在探索可能逆转与衰老和慢性疾病相关损伤的方法。In the anti-aging space, stem cells, regenerative biologics, and senolytic therapies are being studied for their potential to restore tissue function, reduce inflammation, and support healthier aging overall. That shift in focus has sparked major interest from biotech companies and institutional investors alike. 在抗衰老领域，干细胞、再生生物制品和衰老细胞清除疗法正因其恢复组织功能、减少炎症和支持整体健康衰老的潜力而受到研究。这一焦点的转移引起了生物技术公司和机构投资者的极大兴趣。The global cell therapy market was valued at around $4.7 billion in 2023 and is. 2023年全球细胞治疗市场价值约为47亿美元，并且正在增长。expected 预期的to climb past $20 billion by 2030 as more therapies move closer to commercialization. Healthcare companies active in the markets this week include: 到2030年将攀升至超过2000亿美元，因为越来越多的疗法接近商业化。本周在市场活跃的医疗保健公司包括：Avaí Bio, Inc. 阿瓦伊生物公司(OTCQB: (OTCQB:AVAI 可用的), ), Geron Corporation 杰隆公司(NASDAQ: （纳斯达克：GERN 德国海军研究中心), ), BioAge Labs, Inc. 生物时代实验室公司(NASDAQ: （纳斯达克：BIOA 生物应用), ), Lineage Cell Therapeutics, Inc. 系谱细胞治疗公司(NYSE American: LCTX), （纽约证券交易所美国：LCTX），Fate Therapeutics, Inc. 命运治疗公司(NASDAQ: （纳斯达克：FATE 命运). ）。At the same time, the broader longevity and anti-aging market continues gaining momentum as aging populations grow worldwide. Researchers are developing next-generation treatments aimed at removing senescent, or 'zombie,' cells that contribute to aging and disease while also working to regenerate damaged tissue and improve cognitive and physical function later in life. 同时，随着全球老龄化人口的增长，更广泛的长寿和抗衰老市场持续获得动力。研究人员正在开发新一代的治疗方法，旨在清除导致衰老和疾病的衰老或“僵尸”细胞，同时也致力于再生受损组织，并改善晚年的认知和身体功能。Many of these cell-based approaches are now being combined with gene therapies, immune-focused treatments, and personalized medicine strategies to create more targeted solutions. Industry . 许多这些基于细胞的方法现在正与基因疗法、免疫聚焦治疗和个性化医疗策略相结合，以创造更有针对性的解决方案。行业。forecasts 预测suggest the global senolytics and anti-aging pharmaceuticals market could reach approximately $6.39 billion by 2030, driven by rising demand for longevity-focused therapies and growing research into age-related conditions like Alzheimer's and Parkinson's disease. 预计到2030年，全球衰老抑制药物和抗衰老制药市场可能达到约63.9亿美元，主要受到对长寿疗法需求增加以及对阿尔茨海默病和帕金森病等与年龄相关疾病研究不断扩大的推动。Neurodegenerative disorders are also becoming a major area of focus for regenerative medicine as diseases such as Alzheimer's, Parkinson's, ALS, and multiple sclerosis continue to affect millions of people globally. Researchers are studying stem cell and regenerative neural therapies designed to repair damaged neurons, reduce inflammation in the brain, and potentially slow disease progression instead of simply managing symptoms. 神经退行性疾病也正成为再生医学的一个主要关注领域，因为阿尔茨海默病、帕金森病、肌萎缩侧索硬化症（ALS）和多发性硬化症等疾病继续在全球范围内影响数百万人。研究人员正在研究干细胞和神经再生疗法，旨在修复受损的神经元、减轻大脑炎症，并可能减缓疾病进展，而不仅仅是缓解症状。That push toward disease-modifying treatments is attracting substantial investment across both the biotech and pharmaceutical industries. Analysts . 推动疾病修饰治疗的发展，正吸引着生物技术和制药行业大量的投资。分析师们表示。estimate 估计the broader neurodegenerative disease treatment market could grow from roughly $58.4 billion in 2025 to nearly $85 billion by 2032, while smaller niche markets tied to rare neurological disorders are also expected to expand as regenerative medicine technologies continue advancing through clinical development.. 到 2032 年，更广泛的神经退行性疾病治疗市场可能会从 2025 年的大约 584 亿美元增长到近 850 亿美元，而随着再生医学技术在临床开发中不断推进，与罕见神经系统疾病相关的小众市场预计也将扩大。Avaí Bio and Austrianova Complete GMP Master Cell Bank, Begin Viral Testing for Cell-Based Klotho Anti-Aging Therapy Avaí Bio和Austrianova完成GMP主细胞库，开始进行基于细胞的Klotho抗衰老疗法的病毒测试- -Avaí Bio, Inc. (OTCQB: 阿瓦伊生物公司（OTCQB：AVAI 可用的) ('Avaí' or the 'Company'), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced—together with its joint venture partner and global biotechnology firm, Austrianova— a major milestone in the Company's path to clinical trials, the completion of a Master Cell Bank (MCB) of genetically modified cells that overexpress the α-Klotho protein.. ) （“Avaí”或“公司”），一家致力于开发针对糖尿病、年龄相关疾病和抗衰老的变革性细胞疗法的新兴生物技术公司，今天与其合资伙伴及全球生物技术公司Austrianova共同宣布了一项重大里程碑：公司已完成了过表达α-Klotho蛋白的基因修饰细胞主细胞库（MCB），标志着向临床试验迈出了重要一步。Now, the MCB will undergo comprehensive testing to confirm the absence of pathogenic viruses, as well as standard assays to verify the MCB is free from adventitious agents such as bacteria, mycoplasma, fungi, and yeast to meet regulatory expectations, including those set by the FDA. This testing will be conducted independently by a top-tier, accredited third-party provider, separate from Austrianova, Avaí Bio, and their combined joint venture, Klothonova. 现在，MCB将接受全面测试，以确认不存在致病病毒，同时进行标准检测，以验证MCB没有细菌、支原体、真菌和酵母等外源污染，从而满足包括FDA在内的监管要求。此项测试将由一家顶级的、经过认证的第三方机构独立进行，该机构与Austrianova、Avaí Bio及其合资公司Klothonova无关。Following successful completion, the next step will be the generation of a 'Working Cell Bank' (WCB) using α-Klotho protein–overexpressing cells derived from the MCB. These cells will be used to manufacture the final Cell-in-a-Box® encapsulated clinical product.. 成功完成后，下一步将使用来自MCB的α-Klotho蛋白过表达细胞生成“工作细胞库”（WCB）。这些细胞将用于生产最终的Cell-in-a-Box®封装临床产品。A Master Cell Bank is a GMP-compliant, fully characterized, and homogeneous collection of vials derived from a single clone. It serves as the critical starting material for the scale-up and production of cell therapies, ensuring product consistency while reducing risk by protecting against contamination, degradation, extraneous agents, and genetic instability. 主细胞库是一个符合GMP标准、完全特性明确且均匀的单克隆小瓶集合。它作为细胞治疗规模化和生产的起始关键材料，通过防止污染、降解、外来因子和遗传不稳定性，确保产品一致性并降低风险。By establishing and maintaining a high-quality MCB as the primary source for all Working Cell Banks under Good Manufacturing Practice (GMP) standards, Avaí Bio and Austrianova strengthen the foundation for a reliable, scalable, and sustainable supply chain.. 通过建立和维护符合良好生产规范 (GMP) 标准的高质量主细胞库 (MCB)，作为所有工作细胞库的主要来源，Avaí Bio 和 Austrianova 为可靠、可扩展且可持续的供应链奠定了坚实的基础。This milestone marks a significant step forward in Klothonova's mission to develop a sustainable, cell-based approach to restoring declining levels of the α-Klotho 'longevity protein' associated with aging. The approach is intended to address 这一里程碑标志着克洛索诺娃公司在开发一种可持续的、基于细胞的方法来恢复与衰老相关的α-克洛索“长寿蛋白”水平下降方面迈出了重要的一步。该方法旨在解决both general aging 普遍的老龄化and age-related conditions, including kidney disease, neurodegenerative disorders, and 以及与年龄相关的疾病，包括肾病、神经退行性疾病，和vascular diseases 血管疾病. 。'We are pleased that this first step in the production phase of α-Klotho producing cells has been successfully completed. We look forward to the completion of the subsequent steps needed to fulfill our commitment to deliver safe, effective treatments for the ever-burgeoning array of aging associated diseases,' said Chris Winter, Chief Executive Officer of Avaí Bio.. “我们很高兴生产α-Klotho细胞的第一步已经成功完成。我们期待完成后续步骤，以兑现我们为日益增多的与衰老相关的疾病提供安全有效治疗的承诺，”Avaí Bio首席执行官克里斯·温特表示。Dr Brian Salmons, Chief Executive Officer of Austrianova, added, 'The Austrianova team is pleased to have completed the production of the α-Klotho protein expressing cells on behalf of Klothonova, our Joint Venture with Avaí Bio. We look forward to completing the next steps that will culminate with the production of Cell-in-a-Box® encapsulated clinical product for application to patients.'. 奥地利诺瓦公司首席执行官布莱恩·萨蒙斯博士补充道：“奥地利诺瓦团队很高兴代表我们与Avaí Bio的合资企业Klothonova完成了表达α-Klotho蛋白细胞的生产。我们期待完成接下来的步骤，最终将生产出用于患者的Cell-in-a-Box®封装临床产品。”This milestone represents the most recent progress under the joint venture agreement signed in September 2025, which established Klothonova as a Nevada-based company equally owned by Avaí Bio and Austrianova's affiliate, SG Austria Pte. Ltd. The joint venture is dedicated to the sustainable production of α-Klotho—often referred to as the 'longevity protein'—a key regulatory protein widely recognized for its anti-aging properties and protective effects on multiple organs, delivered through encapsulated cell-based therapies for patients. 这一里程碑代表了2025年9月签署的合资协议下取得的最新进展，该协议确立了Klothonova作为一家总部位于内华达州的公司，由Avaí Bio和Austrianova的关联公司SG Austria Pte. Ltd.共同均等拥有。该合资企业致力于通过基于封装细胞疗法为患者提供可持续生产的α-Klotho（通常被称为“长寿蛋白”），这是一种广泛被认为具有抗衰老特性和对多个器官保护作用的关键调控蛋白。. 。CONTINUED… Read this and more news for Avaí Bio at: 继续阅读… 更多关于Avaí Bio的新闻请访问： https://finance.yahoo.com/quote/AVAI/news/ https://finance.yahoo.com/quote/AVAI/news/In other recent developments and happenings in the biotech market include: 生物技术市场其他最近的发展和动态包括：Geron Corporation 杰龙公司(Nasdaq: （纳斯达克：GERN 德国联邦教育与研究部（BMBF）), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, recently ），一家商业阶段的生物制药公司，致力于通过改变血癌的病程来改变患者的生活，最近announced 宣布that the first real-world evidence study of RYTELO® (imetelstat) in patients with lower-risk myelodysplastic syndromes (LR-MDS) will be presented at the European Hematology Association (EHA) 2026 Congress. The retrospective and prospective investigator-sponsored study, conducted at the Moffitt Cancer Center, reported safety and clinical efficacy of imetelstat in advanced, heavily transfusion dependent patients with LR-MDS, including patients with extensive prior therapies and after luspatercept failure. 将在欧洲血液学协会（EHA）2026年大会上展示首个关于 RYTELO®（imetelstat）在低风险骨髓增生异常综合征（LR-MDS）患者中的真实世界证据研究。这项回顾性和前瞻性研究由莫菲特癌症中心开展，报告了 imetelstat 在病情较重、高度依赖输血的 LR-MDS 患者中的安全性和临床疗效，其中包括接受过多种前期治疗和在 luspatercept 治疗失败后的患者。Data from the retrospective portion of the study will be presented at the EHA 2026 Congress.. 研究的回顾性部分数据将在EHA 2026大会上展示。'Imetelstat has become an important treatment option for patients with lower-risk myelodysplastic syndromes experiencing anemia and red blood cell transfusion burden, particularly in patients previously treated with ESAs or other therapies,' said David A. Sallman, M.D., Associate Member, Malignant Hematology Department, Moffitt Cancer Center. “对于患有较低风险骨髓增生异常综合征并伴有贫血和红细胞输注负担的患者，尤其是之前接受过ESA或其他治疗的患者，Imetelstat已成为一种重要的治疗选择，” Moffitt癌症中心恶性血液科副教授David A. Sallman医学博士表示。'As treatment sequencing has emerged as an increasing area of focus in LR-MDS, real-world analyses such as this study can help provide additional context on how therapies are being used in routine clinical practice and across more diverse patient populations. We look forward to presenting these data at EHA 2026.'. “随着治疗排序在低危骨髓增生异常综合征（LR-MDS）中成为日益关注的焦点，像本研究这样的真实世界分析有助于提供关于这些疗法在常规临床实践中的应用及在更多样化患者群体中的使用情况的额外背景信息。我们期待在2026年欧洲血液学协会（EHA）会议上展示这些数据。”BioAge Labs, Inc. 生物时代实验室有限公司(Nasdaq: （纳斯达克：BIOA 生物应用), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, recently )，一家临床阶段的生物制药公司，通过靶向人类衰老生物学来开发治疗代谢性疾病的候选产品，最近reported 已报告results from the Phase 1 clinical trial of BGE-102, a potent, structurally novel, orally available, brain-penetrant small molecule NLRP3 inhibitor. The full dataset, which includes a newly announced 60 mg once-daily cohort dosed for 21 days in participants with obesity and elevated inflammation, demonstrates that BGE-102 achieved potential best-in-class reductions in high-sensitivity C-reactive protein (hsCRP) and consistent reductions across multiple inflammatory biomarkers, with a favorable tolerability profile.. BGE-102是一种强效、结构新颖、可口服、能穿透大脑的小分子NLRP3抑制剂，其一期临床试验结果公布。完整数据集包括一个新宣布的60毫克每日一次、连续21天给药的肥胖伴高炎症受试者队列，结果显示BGE-102在高敏C反应蛋白（hsCRP）方面实现了潜在的同类最佳降低，并在多个炎症生物标志物中表现出一致的降低效果，且具有良好的耐受性。Notably, the 60 mg dose achieved hsCRP and other biomarker reductions comparable to the previously reported 120 mg dose. Based on the full Phase 1 dataset, BioAge intends to initiate a dose-ranging Phase 2 cardiovascular risk proof-of-concept trial in the first half of 2026, with data anticipated in the second half of 2026.. 值得注意的是，60毫克剂量的hsCRP和其他生物标志物的减少与之前报告的120毫克剂量相当。基于完整的1期临床数据集，BioAge计划在2026年上半年启动一项剂量范围的2期心血管风险概念验证试验，数据预计将在2026年下半年公布。Lineage Cell Therapeutics, Inc. 系谱细胞治疗公司(NYSE American: LCTX), a clinical-stage biotechnology company developing 'off the shelf' allogeneic cell therapies for serious medical conditions, recently （纽约证券交易所美国：LCTX），一家临床阶段的生物技术公司，正在开发用于严重医疗状况的“现成”同种异体细胞疗法，最近announced 宣布that 36-month results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089) of RG6501 (OpRegen) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), were presented at the Foundation Fighting Blindness' Retinal Therapeutics Innovation Summit 2026. 36个月的研究结果来自参与RG6501（OpRegen）1/2a期临床研究（ClinicalTrials.gov标识符：NCT02286089）的患者，这些患者患有继发于年龄相关性黄斑变性（AMD）的地图样萎缩（GA），该结果在2026年抗盲基金会的视网膜治疗创新峰会上公布。The presentation, 'Retinal Pigment Epithelium (RPE) Cell Therapy in Geographic Atrophy Secondary to Age-related Macular Degeneration: 3 Year Results from the Phase 1/2a Study,' was presented by Eyal Banin, M.D., Ph.D., Center for Retinal and Macular Degenerations, Department of Ophthalmology Hadassah-Hebrew University Medical Center and Faculty of Medicine, on behalf of Roche and Genentech, a member of the Roche Group.. 《视网膜色素上皮（RPE）细胞治疗因年龄相关性黄斑变性继发的地图样萎缩：1/2a期研究的三年结果》由哈达萨-希伯来大学医学中心眼科系视网膜与黄斑退化中心主任、医学博士Eyal Banin代表罗氏及其成员基因泰克公司发表。'We are excited that our partners continue to collect data and highlight positive clinical results from the OpRegen RPE cell therapy phase 1/2a program,' stated Brian M. Culley, Lineage CEO. 'We remain confident in the potential of OpRegen to address a significant medical need from a single administration, especially because long term clinical outcomes from RPE cell therapy are challenging the long-held view that GA is an irreversible condition, and currently available therapies have not demonstrated a visual benefit. “我们很高兴合作伙伴继续收集数据，并在OpRegen RPE细胞治疗1/2a期项目中突显积极的临床结果，”Lineage首席执行官Brian M. Culley表示。“我们仍然对OpRegen通过单次给药满足重大医疗需求的潜力充满信心，特别是因为RPE细胞治疗的长期临床结果正在挑战长期以来认为GA（地理性萎缩）是不可逆状况的观点，并且目前可用的疗法尚未显示出视觉益处。”The results presented by Dr. Banin include OCT images which indicate partial restoration of outer retinal structure, including the re-appearance of a retinal pigment epithelial layer as well as features associated with recovery of photoreceptors. It remains notable that among patients who received extensive coverage of OpRegen RPE cells across the area of atrophy (n=5), anatomical and functional benefits have lasted for at least three years, outcomes consistent with meaningful disease stabilization and even improvement. 班宁博士展示的结果包括OCT图像，这些图像表明外层视网膜结构的部分恢复，包括视网膜色素上皮层的重新出现以及与光感受器恢复相关的特征。值得注意的是，在那些在萎缩区域广泛覆盖了OpRegen RPE细胞的患者中（n=5），解剖和功能上的益处至少持续了三年，结果表明疾病得到了显著的稳定甚至改善。We are excited to see any additional insights which our partners, Roche and Genentech, may uncover from the ongoing GAlette study, which is a surgical optimization study intended to assess the best way to deliver OpRegen cell therapy to patients with GA secondary to age related macular degeneration.'. 我们很高兴看到我们的合作伙伴罗氏和基因泰克从正在进行的GAlette研究中可能揭示的任何额外见解，这是一项手术优化研究，旨在评估将OpRegen细胞疗法最佳地提供给因年龄相关性黄斑变性而患有GA的患者的方法。Fate Therapeutics, Inc. 命运治疗公司(NASDAQ: （纳斯达克：FATE 命运),a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients for broad accessibility, recently ），这是一家处于临床阶段的生物制药公司，致力于为患者提供一系列变革性的诱导多能干细胞（iPSC）衍生的现货型细胞免疫疗法，以实现广泛的可及性，最近reported 已报告financial results for the first quarter ended March 31, 2026, and provided a business update. 截至2026年3月31日的第一季度财务业绩，并提供了业务更新。'We are incredibly excited and focused on initiating RECLAIM-LN, our Phase 2 potentially registrational clinical trial of FT819 for the treatment of lupus nephritis to provide eligible trial patients a truly accessible CAR T-cell treatment option,' said Bob Valamehr, Ph.D., MBA, President and Chief Executive Officer of Fate Therapeutics. “我们感到无比兴奋，并专注于启动RECLAIM-LN，这是我们FT819二期可能具有注册意义的临床试验，用于治疗狼疮性肾炎，为符合条件的试验患者提供真正可及的CAR T细胞治疗选择，”Fate Therapeutics公司总裁兼首席执行官Bob Valamehr博士、工商管理硕士表示。'Our acceptance into the FDA's highly competitive CDRP Program, combined with our RMAT designation, reflects a recognition of the strength of our initial Phase 1 clinical data and provides a powerful regulatory foundation as we advance FT819 along an accelerated clinical pathway. With planned clinical advancement of FT819 on multiple fronts, next generation CAR T-cell programs entering clinical trials, a strong cash balance supporting our runway into 2028 and a team that continues to execute at the highest level, we believe 2026 will be a defining year for Fate Therapeutics.'. “我们被FDA高度竞争的CDRP计划接受，加上我们获得的RMAT指定，反映了对我们初始第一阶段临床数据实力的认可，并为我们推进FT819沿着加速的临床路径提供了强有力的监管基础。随着FT819在多个方面的计划临床进展、下一代CAR T细胞项目进入临床试验、支持我们到2028年的强大现金余额以及持续高效执行的团队，我们相信2026年将成为Fate Therapeutics的决定性一年。”DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. 免责声明：MarketNewsUpdates.com（MNU）是一家第三方出版商和新闻传播服务提供商，通过多个在线媒体渠道传播电子信息。MNU与本文提及的任何公司均无任何形式的关联。MNU及其附属公司是新闻传播解决方案提供商，并非注册的经纪商/交易商/分析师/顾问，不持有任何投资许可证，且不得出售、要约出售或要约购买任何证券。MNU'S market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU的市场更新、新闻警报和公司简介并非购买、出售或持有证券的招揽或建议。本发布中的材料仅用于严格的信息目的，绝不能被解释或视为研究材料。强烈建议所有读者自行进行研究和尽职调查，并在考虑任何级别的股票投资之前咨询持牌金融专业人士。本文包含的所有材料均为重新发布的内容，详情此前已由本发布中提到的公司传播。MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU expects to be compensated forty nine hundred dollars for news coverage of the current press releases issued by Avaí Bio, Inc.MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.. MNU不对读者或订阅者的任何投资决策负责。投资者应注意，投资股票时可能会损失全部或部分投资。对于当前进行的服务，MNU预计将因对Avaí Bio, Inc.发布的当前新闻稿的报道而获得四千九百美元的报酬。MNU不持有本公告中提及的任何公司的股份。This release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. 本发布包含1933年《证券法》第27A条（经修订）和1934年《证券交易法》第21E条（经修订）所指的“前瞻性声明”，这些前瞻性声明是依据1995年《私人证券诉讼改革法案》的安全港条款作出的。'Forward-looking statements' describe future expectations, plans, results, or strategies and are generally preceded by words such as 'may', 'future', 'plan' or 'planned', 'will' or 'should', 'expected,' 'anticipates', 'draft', 'eventually' or 'projected'. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. “前瞻性声明”描述了未来的预期、计划、结果或策略，通常在这些声明前会有诸如“可能”、“未来”、“计划”或“已计划”、“将”或“应该”、“预期”、“预见”、“草案”、“最终”或“预计”等词语。您应注意，此类声明受到多种风险和不确定性的制约，可能导致未来的实际情况、事件或结果与前瞻性声明中预测的内容有重大差异，包括实际结果可能因各种因素而与前瞻性声明中的预测有重大差异的风险，以及公司在其年度报告Form 10-K或10-KSB中和其他向证券交易委员会提交的文件中指出的其他风险。You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof andMNU undertakes no obligation to update such statements.. 在评估本文件中包含的前瞻性陈述时，您应考虑这些因素，且不应过分依赖此类陈述。本新闻稿中的前瞻性陈述是截至本日期作出的，MNU 没有义务更新这些陈述。Contact Information: 联系信息: Media Contact email: 媒体联系电子邮件：[emailprotected] 电子邮件地址-+1(561)325-8757 - +1(561)325-8757Logo - 标志 -https://mma.prnewswire.com/media/2852558/5980282/Market_News_Updates_Logo.jpg https://mma.prnewswire.com/media/2852558/5980282/Market_News_Updates_Logo.jpgSOURCE Market News Updates 来源 市场新闻更新 21 21% %more press release views with 更多新闻发布视图与 Request a Demo 请求演示